A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens

Presbyopia Clinical Trial

Official title:

A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01959178
• Other study ID #: 825E
• Status: Completed
• Phase: N/A
• Start date: June 2013
• Est. completion date: August 2013

Study information

• Verified date: September 2020
• Source: Bausch & Lomb Incorporated
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate the product performance of the investigational LD127025 MF mid add soft contact lens compared to CIBA Vision's Air Optix Aqua MF MED add soft contact lenses when used among currently adapted soft contact lens wearers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 146
• Est. completion date: August 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Have physiologically normal anterior segments not exhibiting biomicroscopy findings Grade 2 or greater and/or presence of infiltrates.

• Be adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand.

• Be correctable through spherocylindrical refraction to 42 letters (0.1 logMAR) or better (distance, high contrast) in each eye.

• Require contact lens correction from -5.00 D to +3.00 D in each eye.

• Be Presbyopic and require near add correction from +1.00 D to +1.75 D in each eye.

• Be an adapted monovision soft contact lens wearer or multifocal soft contact lens wearer or an adapted spherical soft contact lens wearer who also uses spectacles for near vision correction.

• Be willing to use a lens care system as required by the lens replacement schedule.

• Has a distance spherical equivalent refraction between -5.50 D and +3.00 D.

Exclusion Criteria:

• Not correctable to 32 letters (0.3 logMAR) in each eye with soft spherical contact lenses.

• Participated in any drug or device clinical investigation (within 14 days) prior to entry into this study and/or during the period of study participation.

• Women of childbearing potential if one of the following: pregnant, plans to become pregnant during study, is breast-feeding.

• Any Grade 2 or greater finding during the slit lamp examination. Subjects with corneal infiltrates of ANY GRADE are not eligible.

• Any scar or neovascularization within the central 4mm of the cornea. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgment, does not interfere with contact lens wear, are eligible for this study.

• Any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear.

• Anisometropia (spherical equivalent) of greater than 2.00 D.

• Aphakic.

• Amblyopic.

• Allergic to any component in the study care products.

• Meet any of the following criteria:

• Ophthalmologist, OD, Optician, Ophthalmologist's Assistant/Technician

• employee of a market research firm

• employee of manufacturer of contact lens or contact lens care products

• Ocular astigmatism of greater than 1.00 D in either eye.

• Have had any corneal surgery (ie, refractive surgery).

• Toric contact lens wearer.

• Have worn gas permeable (GP) contact lenses within the last 30 days or PMMA lenses within the last 3 months.

• Have an active ocular disease or are using any ocular medication.

• Have any systemic disease currently affecting ocular health or which, in the Investigator's opinion, may have an effect on ocular health during the course of the study.

• Using any systemic medications that will, in the Investigator's opinion, affect ocular physiology or lens performance.

Related Conditions & MeSH terms

• Presbyopia

Intervention

Device:
• LD127025 MF
At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
• Air Optix Aqua MF
At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.

Locations

Country	Name	City	State
United States	Bausch & Lomb Incorporated	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Visual Acuity	Visual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).	At 1 Week follow up
Secondary	Symptoms/Complaints	Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.	At 1 Week follow up